Objective Intravascular catheter procedures are often performed in patients undergoing antithrombotic therapy. However, methods for the management of antithrombotic agents in the perioperative period are currently unclear. Therefore, the safety and management of antithrombotic agents in these patients were investigated. Methods A prospective, multicenter, observational study [Management of Antithrombotic Agents During Surgery or Medical Procedures with Bleeding (MARK study)] at 58 National Hospital Organization institutions in Japan was performed. 1,040 patients were enrolled in the MARK study and underwent an intravascular catheter procedure. For all participants, the details of the procedure, method of perioperative management of antithrombotic agents, and occurrence of thrombosis, embolism, and bleeding complications during the study period were investigated. Results The use of antithrombotic agents was continued in 1,017 patients (98%, continuation group) and discontinued in the other 23 (2%, discontinuation group). Continuation of the antithrombotic agents did not have a significant effect on the overall occurrence of thromboembolism [hazard ratio (HR), 0.15; p=0.08] or bleeding events (HR, 0.19; p=0.12). However, the overall adverse event risk was significantly lower in the continuation group than in the discontinuation group (HR, 0.18; p=0.03). Conclusion It is both safe and appropriate to perform intravascular catheter procedures in patients continuing with antithrombotic therapy.
Introduction
With the recent aging of the Japanese population, antithrombotic therapy is more often being provided to treat or prevent cardiovascular diseases. Currently, there are an estimated 6 million people taking antiplatelet agents and 1.2 million people taking anticoagulants in Japan. It is therefore likely that more patients are undergoing invasive therapy while receiving antithrombotic therapy. There is already a consensus on the management of antithrombotic agents for tooth extraction (1), cataract surgery (2) , and gastrointestinal endoscopy (3), but a consensus has not yet been reached on antithrombotic therapy for many other invasive medical procedures. It is not uncommon for these patients to undergo intra-arterial catheter procedures [coronary angiography (CAG), percutaneous coronary intervention (PCI), cerebral angiography, leg angiography, etc.]. However, the individual management of antithrombotic therapy during these procedures is based on physician preference, and a standard method has yet to be decided. Theoretically, if an antithrombotic agent is discontinued, it is possible to perform the procedure smoothly without excessive bleeding, however, the risk of thrombosis and embolism increases. Conversely, if the antithrombotic agent is continued, perioperative thrombosis and embolism can be prevented, but the risk of bleeding increases. It has been reported that the cessation of warfarin results in serious thromboembolism in 1% of patients and death in 80% of this 1%; the cessation of aspirin leads to a 3.4-fold increase in the odds ratio for cerebral infarc-tion (4, 5) . A sub-analysis in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study of secondary stroke prevention also found that cessation of antiplatelet agents resulted in approximately a 5-fold increase in the incidence of stroke recurrence within one week (6) . In regard to antithrombotic therapy for catheter procedures, patients undergoing catheter ablation to treat atrial fibrillation (AF) showed no cerebral infarctions in the warfarin continuation group and no increase in bleeding complications compared to the heparin bridging therapy group (7). However, there have so far been no large-scale studies on other intravascular catheter procedures. The objectives of the present study were to investigate the safety and management of antithrombotic agents in patients who underwent intravascular catheter procedures.
Meterials and Methods
Data from the Management of Antithrombotic Agents During Surgery or Medical Procedures with Bleeding Study (MARK study) (8) were used for this study. The MARK study is a multicenter and observational study to survey the safety and management of antithrombotic agents during surgery or medical procedures with bleeding at 58 National Hospital Organization institutions in Japan. The MARK study database is maintained at the National Hospital Organization.
Participants
The target subjects were 1,051 patients who underwent an intravascular catheter procedure in 18 institutes (Supplementary material) from among 8,456 patients enrolled in the MARK study in 58 institutes between December 2011 and December 2013. The participants received antithrombotic therapy (antiplatelet agent, anticoagulant, or both) for a disease [AF, mitral valve stenosis, post-mitral valve replacement, post-aortic valve replacement, ischemic heart disease (IHD), cerebral infarction, blockage of head and neck arteries, " 50% stenosis of cerebral and cervical arteries, transient cerebral ischemia, peripheral arterial disease, deep venous thrombosis, pulmonary embolism, or other thromboembolic disorders]. All of the patients gave their written consent for this study. The National Hospital Organization (Japan) ethics committee approved the MARK study.
Investigation
Clinical data, including the details of intravascular catheter procedures, the target disease for antithrombotic agents, the underlying disease, details of antithrombotic agents before the procedure, and the management method of antithrombotic agents at the time of the procedure (continuation, cessation, alternative treatment) were examined in each patient. The intravascular catheter procedures included CAG, PCI, cerebral angiography, carotid artery stenting, cerebral aneurysm coil embolization, other angiography, and percutaneous transluminal angioplasty (PTA). The antithrombotic agents were divided into antiplatelet agents and anticoagulants, with aspirin, clopidogrel, ticlopidine, cilostazol, dipyridamole, limaprost alfadex, sarpogrelate, beraprost sodium, and ethyl icosapentate defined as antiplatelet agents, and warfarin and dabigatran defined as anticoagulants.
The occurrence of thromboembolic events and bleeding disorders, as well as the bleeding volume, from 2 weeks before the procedure to 4 weeks after the procedure was also investigated for each antithrombotic management method. A thromboembolic event was defined as ischemic stroke (acute brain infarction/transient ischemic attack), acute myocardial infarction, unstable angina, pulmonary embolism, or deep vein thrombosis. A bleeding event was defined as intracranial hemorrhage (acute brain hemorrhage/acute subarachnoid hemorrhage/subdural hemorrhage), gastrointestinal hemorrhage, or other bleeding (striking wound bleeding or ecchymoma). Total adverse events were defined as including death, all thromboembolic events, and all bleeding events. The management of the antithrombotic agents was determined individually by each physician. The antithrombotic agent continuation group was defined as the group of patients who continued to take all the antithrombotic agents that they were taking when they enrolled in the study throughout the study period, and the discontinuation group was defined as the group of patients who discontinued one or more of the antithrombotic agents that they were taking at study enrollment. This group included patients who underwent heparin bridging therapy.
Statistical analysis
Continuous variables are expressed as the means ± standard deviation. Categorical variables are expressed as actual values and percentages. The Mann-Whitney U test, chisquare test, and analysis of variance (ANOVA)/Scheffe's test were used, as appropriate, for intergroup comparisons. The incidence rates of perioperative thromboembolic events, bleeding complications, and overall adverse events were compared using the chi-square test, but when there was a 2× 2 frequency table with a small number (! 5) of expected frequencies in one or more cells, Fisher's exact test was used. The StatView 5.0 system (SAS Institute, Cary, USA) was used for the analysis and the significance level was set at p< 0.05.
Results
After excluding 11 patients who were lost to follow-up after undergoing an intravascular catheter procedure, the analysis set consisted of 1,040 patients. The intravascular catheter procedures included CAG in 602 patients, PCI in 288 patients, cerebral angiography in 58 patients, and other procedures in 92 patients (leg angiography, leg PTA, other PTA, cerebral intravascular treatment, other angiography, or abdominal aortic stent grafting). The disease targeted by antithrombotic therapy was IHD in 870 patients, AF in 108 patients, transient ischemic attack (TIA)/cerebral infarction in 132 patients, and peripheral arterial disease (PAD) in 111 patients. IHD and dyslipidemia were common among patients undergoing CAG/PCI, while TIA/cerebral infarction was common and diabetes was rare among patients undergoing cerebral angiography. The morbidity rates for hypertension and AF were not significantly different between the patients undergoing different procedures ( Table 1) .
Details of antithrombotic agents
Of the 1,040 patients receiving antithrombotic therapy at study registration, 302 (29.0%) were taking a single antiplatelet agent (Single AP), 602 (57.9%) were taking two or more antiplatelet agents (Multiple APs), 39 (3.8%) were taking a single anticoagulant (AC alone), and 97 (9.3%) were taking antiplatelet agents and anticoagulants together (AP+ AC). Examining each intravascular catheter procedure separately, many patients in the CAG group (318 patients, 52.8%), the PCI group (216 patients, 75.0%), and the other catheter procedure groups (48 patients, 52.2%) were in the Multiple APs group. In contrast, in the cerebral angiography group, most patients were categorized as "Single AP" (28 patients, 48.3%) ( Table 1 ). In the Single AP group, the most common agent was aspirin (76.8%) followed by the thienopyridines (14.9%). In the Multiple APs group, the most common combination was aspirin and a thienopyridine (87.2%). In the AC alone group, 31 (79.5%) patients took warfarin and 8 (20.5%) patients took dabigatran. In the AP+ AC group, the most common combinations of antiplatelet agent and anticoagulant were warfarin, aspirin and thienopyridine (39.2%), followed by warfarin and aspirin (30.9%) ( Table 2) .
Perioperative management of antithrombotic agents
The vast majority (1,017, 97.8%) of the 1,040 patients underwent an intravascular catheter procedure while continuing with antithrombotic therapy. The antithrombotic agent continuation rate by intravascular catheter procedure was 98.8% (595 patients) in the CAG group, 95.8% (276 patients) in the PCI group, 100.0% (58 patients) in the cerebral angiography group, and 95.7% (88 patients) in the other catheter procedure group. The antithrombotic agent continuation rate by agent was high, 99.3% (300 patients) in the Single AP group, 99.5% (599 patients) in the Multiple APs group, and 94.9% (37 patients) in the AC alone group; however, in the AP+AC group, the rate was relatively low, 83.5% (81 patients), when compared to the other groups (p< 0.0001). Only 23 patients were in the discontinuation group. The median discontinuation period was 1.5 days [interquartile range (IQR) 1.0 to 6.5].
Perioperative complications
There were two deaths among the 1,040 patients. Both patients had continued taking multiple antiplatelet agents. One died from a cerebral hemorrhage 18 days after undergoing CAG, and the other died from aggravation of heart failure on the 9th day after CAG for chronic heart failure ( Table 3, 4) .
Thromboembolic events were reported in 6 patients [2 acute myocardial infarctions (AMI) and 4 cerebral infarctions] (Table 3, 4) . Five of these events occurred in the continuation group, with 1 (0.1%) AMI and 4 (0.4%) cerebral infarctions. The AMI in the continuation group occurred 8 days after CAG in a patient taking aspirin alone. The cere- bral infarctions in the continuation group occurred in 3 patients who underwent cerebral angiography and 1 patient who underwent leg angiography. In patient 1, cerebral infarction occurred the day after carotid endarterectomy, which was performed 9 days after cerebral angiography, while taking aspirin monotherapy; in patient 2, cerebral infarction occurred 23 days after cerebral angiography while taking aspirin + clopidogrel; in patient three, cerebral infarction occurred 3 days after cerebral angiography while taking ticlopidine; and in patient 4, cerebral infarction occurred the day the patient underwent leg angiography while taking aspirin. Conversely, in the discontinuation group (including alternative treatment), AMI occurred on the day of PCI in 1 (4.3%) patient who had stopped taking aspirin and ticlopidine 1 week before the procedure and was receiving alternative treatment with heparin.
Bleeding complications were seen in 9 patients (2 cerebral hemorrhages, 2 gastrointestinal hemorrhages, 4 wound site bleeds/hematomas, and 1 iliac artery puncture). Eight (0.8%) of these events occurred in the continuation group and 1 (4.3%) in the discontinuation group. Both cases of cerebral hemorrhages were in the continuation group, occurring in one patient the day after catheter intervention for an internal carotid aneurysm performed while continuing clopidogrel, and in the second patient, 18 days after CAG was performed while taking aspirin and clopidogrel. This second patient died. Both cases of gastrointestinal hemorrhages occurred in patients who underwent PCI while taking aspirin and clopidogrel. The only bleeding complication in the discontinuation group was hematoma formation in one patient (Table 3, 4) .
The incidence rate of bleeding events in the continuation group was not high compared with that in the discontinuation group, regardless of the procedure and antithrombotic therapy. With respect to the thromboembolic events, the incidence rate was not different between the groups overall. However, the incidence rate of myocardial infarction was significantly higher in the patients in the discontinuation group who underwent PCI, though it occurred in only one patient in the group. The frequency of all adverse events was significantly lower in the continuation group than in the discontinuation group (1.4% vs. 
Discussion
The number of patients with pathologies requiring antithrombotic therapy has increased as the population has aged, resulting in the more frequent use of intravascular catheter procedures for diagnosis and treatment. However, there is almost no evidence from prospective studies in Japan on the management of antithrombotic agents when performing intravascular catheter procedures. In regard to the use of anticoagulant therapy when performing catheter ablation for AF, the continuation of warfarin has been found to lower the risk of perioperative cerebral infarction, without any increase in bleeding complications, when compared to heparin bridging therapy (7); however, it remains unclear for other intravascular catheter procedures. In this study, a prospective registration study was performed to investigate the current state of antithrombotic agent management and the occurrence of perioperative complications in Japan when performing intravascular catheter procedures.
As many as 83.7% of all study subjects had a history of IHD, as evidenced by the fact that 85.6% of the subjects had undergone CAG or PCI. Because patients with IHD often take powerful antiplatelet agents, and many such patients were included in the study, patients taking two or more antiplatelet agents were the most common and accounted for 57.9% of all subjects. Conversely, a single antiplatelet agent was the most common therapy in the cerebral angiography group, which included a large number of ischemic stroke patients. This is, however, an expected result, since multiple antiplatelet agents or the coadministration of antiplatelet agents and anticoagulants leads to an increase in intracranial bleeding and life-threatening severe bleeding in patients with a history of cerebrovascular disorders (9) (10) (11) .
The perioperative management of antithrombotic agents was decided by each medical institution and each patient's physician, but in the majority of patients, antithrombotic agents were continued regardless of the nature of the intravascular catheter procedure. However, in the AP+AC group, 16.5% of the patients had one of the antithrombotic agents discontinued, which was a significantly higher discontinuation rate than in the other antithrombotic therapy groups (p<0.0001). In the group of 16 patients taking antiplatelet agents and anticoagulants together, 1 patient discontinued all antithrombotic agents, 14 discontinued the anticoagulants only, and 1 discontinued the antiplatelet agents only. In the AP+AC group, anticoagulants tended to be selected in favor of antiplatelet agents when considering drug withdrawal because of the risk of increased bleeding volume and bleeding complications at surgery. However, the fact that the median withdrawal time was short (1 day, IQR 1-2.3) in the majority of patients may have been because intravascular catheter procedures are less invasive than surgical treatments. Furthermore, the physician would have been aware of the risk of thromboembolism due to discontinuation.
With respect to the safety of intravascular catheter procedures in patients continuing antithrombotic therapy, the incidence rate of all thromboembolic events was not different from that in the discontinuation group. There are three possible reasons for this. First, the number of thromboembolic events was small due to the very small number of subjects in the discontinuation group; second, only 5 of 23 patients in the discontinuation group discontinued all antithrombotic agents (1 of whom received heparin bridging therapy), so thromboembolic events may have been suppressed in the other 18 patients with the continuation of another antithrombotic agent; and third, the median withdrawal period of 1.5 days (IQR 1.0-6.5) may have been too short to allow the clot formation and growth that could cause thromboembolic events. With respect to the occurrence of thromboembolic events due to the discontinuation of antithrombotic agents, studies have reported rates of 4.49% for ischemic stroke due to the withdrawal of antithrombotic agents (12), 2.3-4.1% for acute coronary syndrome due to the withdrawal of aspirin (13) , and 1% for thromboembolic events due to the withdrawal of warfarin (4). Our findings did not greatly differ from the previous studies; AMI occurred in 1 patient (4.3%) in the discontinuation group. With respect to the period from the withdrawal of antithrombotic agents to the occurrence of thromboembolic events, one study reported that about 70% of post-withdrawal cerebral infarctions occurred within 10 days after withdrawal (5) , and the PRoFESS study sub-analysis found that there was a significantly higher stroke recurrence rate within 1 week after the withdrawal of antiplatelet agents (6) . In the present study, the patient in the discontinuation group who suffered AMI had discontinued all antithrombotic agents (aspirin and ticlopidine) 1 week earlier and was receiving heparin bridging therapy, but suffered AMI on the day of the procedure (7th day of withdrawal), a similar result to previous studies. The present study found no significant difference in the risk of overall thromboembolic events between the continuation group and the discontinuation group, but it suggested that withdrawal could increase the risk of AMI.
Alternatively, there were concerns that bleeding complications would increase as a result of continuing the antithrombotic agents, but the present study found no significant difference in the incidence rate of overall bleeding complications between the two groups (0.8% vs. 4.3%, p=0.183). There was also no significant intergroup difference in the bleeding volume during intravascular catheter procedures. The incidence rate of overall adverse events, including deaths, all thromboembolic events, and all bleeding complications, was significantly lower in the continuation group, a result which provides further evidence of the safety of intravascular catheter procedures in patients continuing antithrombotic therapy.
Study limitations
There were several limitations associated with this study. First, the small number of patients in the antithrombotic agent discontinuation group made it difficult to properly analyze difference between the continuation and discontinuation group. Although more patients who discontinue the use of antithrombotic agents are necessary, the discontinuation of antithrombotic agents for intravascular catheter procedures could increase the risk of thromboembolic events and adverse events, as suggested in our study. Furthermore, because the risk of bleeding complications was similar amongst the continuation and discontinuation groups, it will be difficult in practice to conduct research with a large number of patients in the discontinuation group. Second, the reasons for discontinuation of antithrombotic agents in the discontinuation group patients were unknown. Therefore, it was not possible to analyze the effects of each patient's condition in the discontinuation group on the outcome of this study. The current study was a prospective observational study of perioperative complications associated with the continuation and discontinuation of antithrombotic therapy, and it gave a clear picture of the management of antithrombotic therapy when performing intravascular catheter procedures in Japan. Further studies to evaluate and investigate the management of antithrombotic agents in other invasive procedures are planned.
Conclusion
The safety of intravascular catheter procedures in patients continuing antithrombotic therapy was confirmed in a study covering a large number of institutions and patients in Japan. Intravascular catheter procedures can be considered appropriate in patients continuing with antithrombotic therapy.
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